Confo Therapeutics Announces Selection of First Product Candidate and Initiation of Pre-Clinical Development

Confo Therapeutics today announced the selection of its first preclinical drug candidate, CFTX-1554, a compound designed to address peripheral neuropathic pain with the potential to address additional pain indications. Confo has applied its proprietary, fragment-based drug discovery and structure-guided drug design technologies to identify CFTX-1554, a novel inhibitor of angiotensin II type 2 receptor, or AT2R, a clinically validated target for the treatment of neuropathic pain. The Company has initiated Phase I-enabling studies and aims to advance CFTX-1554 to clinical development upon successful completion of these studies. As the Company’s first discovery program ready to enter preclinical evaluation, the selection of CFTX-1554 marks the achievement of a significant corporate milestone in the development of Confo’s internal pipeline. CFTX-1554 represents one of many compounds that the Company will continue to evaluate as a means of addressing a range of underserved indications.

Current treatments for peripheral neuropathic pain are lacking in efficacy and often result in severe side-effects including sedation, addiction and/or respiratory depression. In addition, the development of new therapeutics is hampered by the lack of mechanistic understanding of this condition. While AT2R is a verified target for neuropathic pain, clinical-stage compounds that have been tested to date have failed to progress due to side effects and/or toxicity concerns. While targeting the same pathway, CTFX-1554 more efficiently interacts with the AT2R binding site, resulting in improved drug-like properties.

Confo believes that this previously unexplored binding site interaction holds the potential for its lead compound to be both safe and efficacious in a disease area with severely limited treatment options.

“Recent pharmaceutical efforts testing an AT2R antagonist have achieved clinical proof-of-concept in treating neuropathic pain but resulted in problems with safety and tolerability. By leveraging our rational drug design and small molecule expertise to identify and create CFTX-1554, we believe this novel chemical entity could better and more safely inhibit AT2R as a validated target in neuropathic pain,” said Christel Menet, CSO of Confo Therapeutics. “Although we are in the first stage of proving the potential of this compound, we have made a large step forward as an organization toward applying our technology to solve pharmacological challenges.”

Commenting on the selection, Paolo Vicini, CDO of Confo Therapeutics added: “Peripheral neuropathic pain can manifest as a result of a variety of conditions including diabetic peripheral neuropathy and chemotherapy-induced neuropathy. Based on its unique pharmacology, we see CFTX-1554 as a differentiated therapeutic option with the potential to help patients suffering from debilitating neuropathic pain and potentially even inflammatory pain. We look forward to advancing CFTX-1554 through preclinical development.”

For more information, visit www.confotherapeutics.com


Jérôme Van Biervliet, Managing Director at VIB

“We heartily congratulate VIB spin-off Confo Therapeutics with the selection of their first preclinical drug candidate. Confo is definitely playing to win with their growing, multi-indication pipeline of drug candidates.”

Share this story